A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma
- Sponsor
- Hebei Medical University Fourth Hospital
- Study ID
- NCT03320629
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Refractory or Metastatic Esophageal Squamous Cell Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- apatinib S-1 radiotherapy — COMBINATION_PRODUCTapatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
- S-1 radiotherapy — COMBINATION_PRODUCTS-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
Study Details
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus radiotherapy and S-1 for treatment of refractory or metastatic esophageal squamous cell carcinoma.
Key Dates
- Start date
- Nov 1, 2017
- Status verified
- Oct 2017
- Primary completion
- Nov 1, 2017
- Completion
- Dec 31, 2018
Study Design
- Enrollment
- 7 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: apatinib and S-1 radiotherapyapatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
- Active Comparator: S-1 radiotherapyS-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
Primary Outcome Measure
Progression free survival [ Time Frame: evaluated in 24 months since the treatment began ]